CSTONE PHARMA-B
- Country
- 🇭🇰Hong Kong, China
- Ownership
- -
- Established
- 2018-12-13
- Employees
- 164
- Market Cap
- -
- Website
- http://www.cstonepharma.com
- Introduction
Cornerstone Pharmaceutical was created to meet the needs of cancer patients and focuses on developing and commercializing innovative tumor immunotherapy and molecular-targeted drugs. Since its establishment 3 years ago, the company has assembled a world-class management team with rich experience in preclinical research, clinical development and commercializa...
A Study of CS1001 in Subjects With Stage III Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-11-02
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- CStone Pharmaceuticals
- Target Recruit Count
- 381
- Registration Number
- NCT03728556
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
A Study of CS1001 in Subjects With Relapsed or Refractory Extranodal Natural Killer/ T Cell Lymphoma(ENKTL)
- First Posted Date
- 2018-07-23
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- CStone Pharmaceuticals
- Target Recruit Count
- 80
- Registration Number
- NCT03595657
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, China
🇨🇳Shanghai East Hospital, Shanghai, China
🇨🇳Peking University Third Hospital, Beijing, China
A Study of CS1002 in Subjects With Advanced Solid Tumors
- First Posted Date
- 2018-05-14
- Last Posted Date
- 2022-12-16
- Lead Sponsor
- CStone Pharmaceuticals
- Target Recruit Count
- 91
- Registration Number
- NCT03523819
- Locations
- 🇦🇺
Southern Medical Day Care Centre, Wollongong, New South Wales, Australia
🇦🇺Boxhill Hospital, Melbourne, Victoria, Australia
🇦🇺St Vincent's hospital, Sydney, New South Wales, Australia
A Study of CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2018-05-04
- Last Posted Date
- 2021-01-12
- Lead Sponsor
- CStone Pharmaceuticals
- Target Recruit Count
- 18
- Registration Number
- NCT03516123
- Locations
- 🇦🇺
St Vincent's hospital, Sydney, New South Wales, Australia
A Study of CS1001 in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma
- First Posted Date
- 2018-04-23
- Last Posted Date
- 2022-10-31
- Lead Sponsor
- CStone Pharmaceuticals
- Target Recruit Count
- 82
- Registration Number
- NCT03505996
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
A Study of CS1003 in Subjects With Advanced Solid Tumors
- First Posted Date
- 2018-03-23
- Last Posted Date
- 2022-02-18
- Lead Sponsor
- CStone Pharmaceuticals
- Target Recruit Count
- 108
- Registration Number
- NCT03475251
- Locations
- 🇦🇺
Scientia Clinical Research Ltd, Randwick, New South Wales, Australia
A Phase Ia/Ib Study of CS1001 in Subjects With Advanced Solid Tumors
- First Posted Date
- 2017-10-18
- Last Posted Date
- 2022-05-26
- Lead Sponsor
- CStone Pharmaceuticals
- Target Recruit Count
- 259
- Registration Number
- NCT03312842
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China